
A Psychedelic Breakthrough In the Treatment of Trauma and Addiction | Dr. Nolan Williams
Apr 26, 2024
Dr. Nolan Williams discusses a clinical trial using ibogaine to treat veterans with PTSD and addiction, achieving an 83% remission rate. They explore the unique effects of ibogaine compared to classic psychedelics, the potential for combating addiction, and the therapeutic journey individuals undergo with ibogaine treatment.
AI Snips
Chapters
Transcript
Episode notes
Real-World Trial Built From Veteran Demand
- Nolan Williams built a trial around veterans who traveled to Mexico for ibogaine and performed deep neurobiology measures.
- Many returned with resolution of PTSD, depression, anxiety, and even traumatic brain injury–an unprecedented result.
Veterans' Trips Sparked The Trial
- The study arose because veterans traveled to Tijuana to self-administer ibogaine and reported strong benefits.
- Williams' team then constructed the first neurobiology trial to systematically study those outcomes.
Ibogaine Produces A Consistent Life Review
- Ibogaine is an alkaloid from a West African shrub that at high doses induces a stereotyped life-review experience.
- The drug consistently guides veterans through emotionally salient memories that support therapeutic recontextualization.

